glp-1 cardiovascular outcomes news Protective Properties of Receptor Agonists: More than Just Diabetic and Weight Loss Drugs Results of cardiovascular outcomes trials

I thought that was a little interesting thing that I learned

Most events were reported as mild-to-moderate and concentrated during dose escalation

Gastric inhibitory polypeptide competes with glucagon for binding to the glucagon receptor and can inhibit glucagon-stimulated lipolysis in adipocytes, indicating that glucagon mediates lipolysis, at least in part, through direct activation of its receptor (27)

Endogenous and exogenous hydrogen sulfide promotes resolution of colitis in rats

Because ipamorelin does not have these effects, patients can benefit from just the positive aspects of GH therapy while keeping unwanted side effects at bay

BMI requirements may apply for insurance coverage of GLP-1 drugs when prescribed specifically for weight management rather than diabetes